| pubmed-article:8538171 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C0225336 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C0001511 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C0596138 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C1515406 | lld:lifeskim |
| pubmed-article:8538171 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:8538171 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8538171 | pubmed:dateCreated | 1996-2-8 | lld:pubmed |
| pubmed-article:8538171 | pubmed:abstractText | Other investigators have shown that exogenously administered transforming growth factor-beta (TGF-beta) inhibits lymphocyte adherence to vascular endothelial cells (VEC). We examined the role of TGF-beta 1 as an autocrine mediator of lymphocyte adhesion to adult human VECs. VECs were harvested from eight saphenous or cadaveric iliac veins using 0.2% collagenase. Low-passage VECs in MCDB + 0.1% BSA were pretreated for 24 hr with monoclonal anti-TGF-beta 1 antibody (5 micrograms/ml), LPS (5 micrograms/ml), or IL-1 (10 U/ml). Adherence of fluorescently labeled lymphocytes to pretreated VECs was quantitated and results were expressed as relative adhesion compared to untreated control. Total mRNA from LPS- or IL-1-treated VECs was subjected to Northern analysis to determine relative TGF-beta 1 expression. Total TGF-beta 1 protein concentration in supernatants from LPS- or IL-1-treated VECs was determined by ELISA. Data (means +/- SEM) were analyzed by ANOVA with a Newman-Keuls posttest. Neutralizing endogenous TGF-beta 1 with anti-TGF-beta 1 antibody significantly increased adhesion of lymphocytes to VEC monolayers compared to control (125 +/- 3 vs 101 +/- 2%, P < 0.01, n = 8). The level of adhesion was equivalent to that seen with IL-1 stimulation (131 +/- 6%). Spearman correlation of lymphocyte adherence to IL-1- or LPS-treated VECs vs TGF-beta 1 mRNA expression or vs relative TGF-beta 1 protein concentration showed significant inverse relationships (r = -0.82, P < 0.001, and r = -0.87, P < 0.001, respectively). Endogenous TGF-beta 1's inhibitory effect on lymphocyte adhesion was blocked by a specific neutralizing antibody. VEC TGF-beta 1 mRNA expression and TGF-beta 1 production were inversely proportional to lymphocyte adhesion, suggesting down-regulation of TGF-beta 1 in response to proinflammatory cytokines. Together, these observations support the hypothesis that TGF-beta 1 has an autocrine inhibitory role in regulation of lymphocyte adhesion to VECs. | lld:pubmed |
| pubmed-article:8538171 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8538171 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8538171 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8538171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8538171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8538171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8538171 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8538171 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:8538171 | pubmed:issn | 0022-4804 | lld:pubmed |
| pubmed-article:8538171 | pubmed:author | pubmed-author:RhodesJ MJM | lld:pubmed |
| pubmed-article:8538171 | pubmed:author | pubmed-author:GiffordR RRR | lld:pubmed |
| pubmed-article:8538171 | pubmed:author | pubmed-author:EngelmyerEE | lld:pubmed |
| pubmed-article:8538171 | pubmed:author | pubmed-author:TilbergA FAF | lld:pubmed |
| pubmed-article:8538171 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8538171 | pubmed:volume | 59 | lld:pubmed |
| pubmed-article:8538171 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8538171 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8538171 | pubmed:pagination | 719-24 | lld:pubmed |
| pubmed-article:8538171 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:meshHeading | pubmed-meshheading:8538171-... | lld:pubmed |
| pubmed-article:8538171 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8538171 | pubmed:articleTitle | Transforming growth factor-beta 1 serves as an autocrine inhibitor of human endothelial cell/lymphocyte adhesion. | lld:pubmed |
| pubmed-article:8538171 | pubmed:affiliation | Department of Surgery, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey 17033, USA. | lld:pubmed |
| pubmed-article:8538171 | pubmed:publicationType | Journal Article | lld:pubmed |
